US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Hls Therapeutics Inc (TSX:HLS)

4.210 +0.340 (+8.79%)
Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hls Therapeutics Inc

News headline image
HLS Therapeutics Q2 Earnings Call Highlights ↗
HLS Therapeutics (TSE:HLS) reported second-quarter fiscal 2026 revenue growth as its cardiovascular portfolio expanded 25% year over year, led by continued gains for Vascepa and the first full quarter... 
Via MarketBeat
Topics Earnings
News headline image
HLS Therapeutics Q1 Earnings Call Highlights ↗
HLS Therapeutics (TSE:HLS) reported modest first-quarter revenue growth and reaffirmed its 2026 outlook, while management highlighted early momentum for the company’s newly launched cholesterol drug... 
Via MarketBeat
Topics Earnings
News headline image
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
3 Top Canadian Pharmaceutical Stocks In April 2023 ↗
When investors discuss striking it rich in the stock market, they often discuss a few industries. One of them being technology and the other being pharmaceutical stocks. 
Via Talk Markets
News headline image
Sidoti Winter Virtual Small Cap Investor Conference
- Presentation Times and Weblinks Released for Over 70 Presenting Companies - Wednesday and Thursday, January 19th-20th, 2022 NEW YORK, NY / ACCESSWIRE / January 18, 2022 / Sidoti & Company, LLC has... 
From Sidoti & Company, LLC
Via AccessWire
News headline image
This Pharmaceutical Company Just Got a Major Boost ↗
Big-time name recognition could lead to big gains for HLS and its investors. 
Via The Motley Fool